Last reviewed · How we verify

Azienda Sanitaria dell'Alto Adige — Portfolio Competitive Intelligence Brief

Azienda Sanitaria dell'Alto Adige pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fentanyl ev Fentanyl ev marketed Synthetic opioid agonist Mu-opioid receptor (OPRM1) Pain management, Anesthesia

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Boston Medical Center · 1 shared drug class
  2. L'Hospitalet de Llobregat · 1 shared drug class
  3. Oregon Health and Science University · 1 shared drug class
  4. University Hospital, Ghent · 1 shared drug class
  5. University of Maryland, Baltimore · 1 shared drug class
  6. Virginia Commonwealth University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Azienda Sanitaria dell'Alto Adige:

Cite this brief

Drug Landscape (2026). Azienda Sanitaria dell'Alto Adige — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-sanitaria-dell-alto-adige. Accessed 2026-05-17.

Related